PAQ Therapeutics, a Burlington, MA-based biotechnology company developing KRAS degraders, raised $39M in Series B funding.
The round was led by Bayland Capital and MRL Ventures Fund (MRLV), with participation from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), LAV Fund, BioTrack Capital, and existing investor Sherpa Health Partners.
The company intends to use the funds to support the next stage of clinical development for its lead asset PT0253.
Led by CEO Nan Ji, PAQ Therapeutics is a clinical-stage biotechnology company developing KRAS degraders for lethal cancers lacking effective treatment options. Founded in 2020, the company had completed a $30M Series A financing in 2021.
FinSMEs
07/05/2025